Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desogestrel
Drug ID BADD_D00618
Description Desogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada.[A176339] It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activity.[T521] Desogestrel is now produced semi-synthetically from naturally occurred plant steroids.[F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].[A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762]
Indications and Usage For the prevention of pregnancy in women who elect to use this product as a method of contraception.
Marketing Status Not Available
ATC Code G03AC09
DrugBank ID DB00304
KEGG ID D02367
MeSH ID D017135
PubChem ID 40973
TTD Drug ID D06CGB
NDC Product Code 60870-0460; 55486-1569; 45541-1191; 63190-0070; 63190-0770
Synonyms Desogestrel | 13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol | 13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol | alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17 | 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17alpha)- | Org-2969 | Org 2969 | Org2969 | Marvelon | Cerazette
Chemical Information
Molecular Formula C22H30O
CAS Registry Number 54024-22-5
SMILES CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CCCCC34
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Alopecia23.02.02.001--
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Breast discharge21.05.05.001--Not Available
Breast enlargement21.05.04.001--Not Available
Breast pain21.05.05.003--
Breast tenderness21.05.05.004--Not Available
Cataract06.06.01.001--
Chloasma23.05.01.001; 18.08.02.002--Not Available
Contact lens intolerance06.01.01.003--Not Available
Depressed mood19.15.02.001--Not Available
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Erythema nodosum23.07.02.001; 10.02.01.020--Not Available
Eye disorder06.08.03.001--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Hepatic neoplasm16.07.03.001; 09.04.03.001--Not Available
Hirsutism23.02.04.001; 05.05.01.005--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Immune system disorder10.02.01.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Libido increased21.03.02.007; 19.08.03.002--
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood swings19.04.03.001--Not Available
Nausea07.01.07.001--
The 1th Page    1 2    Next   Last    Total 2 Pages